anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mucopolysaccharidosis type II (MPSII) is a rare pediatric X-linked lysosomal storage disease, caused by heterogeneous mutations in the iduronate-2-sulfatase (IDS) gene, which result in accumulation of heparan sulfate (HS) and dermatan sulfate within cells. This leads to severe skeletal abnormalities, hepatosplenomegaly, and cognitive deterioration. The progressive nature of the disease is a huge obstacle to achieve full neurological correction. Although current therapies can only treat somatic symptoms, a lentivirus-based hematopoietic stem cell gene therapy (HSCGT) approach has recently achieved improved central nervous system (CNS) neuropathology in the MPSII mouse model following transplant at 2 months of age. In this study, we evaluate neuropathology progression in 2-, 4- and 9-month-old MPSII mice, and using the same HSCGT strategy, we investigated somatic and neurological disease attenuation following treatment at 4 months of age. Our results showed gradual accumulation of HS between 2 and 4 months of age, but full manifestation of microgliosis/astrogliosis as early as 2 months. Late HSCGT fully reversed the somatic symptoms, thus achieving the same degree of peripheral correction as early therapy. However, late treatment resulted in slightly decreased efficacy in the CNS, with poorer brain enzymatic activity, together with reduced normalization of HS oversulfation. Overall, our findings confirm significant lysosomal burden and neuropathology in 2-month-old MPSII mice. Peripheral disease is readily reversible by LV.IDS-HSCGT regardless of age of transplant, suggesting a viable treatment for somatic disease. However, in the brain, higher IDS enzyme levels are achievable with early HSCGT treatment, and later transplant seems to be less effective, supporting the view that the earlier patients are diagnosed and treated, the better the therapy outcome.
Giomer resin not only reduces the risk of secondary caries around restorations by releasing fluoride ions, but it also has good esthetic, physical, and handling features. Furthermore, advancements have been made to reduce giomer resin polymerization shrinkage by incorporating filler technology into the matrix system. As a result of these efforts, giomer resin is currently distinguished by its low shrinkage feature. According to the manufacturer, low shrinkage giomer resin has volumetric shrinkage of 0.8% and a polymerization shrinkage stress of 2.72 MPa. Several investigations were carried out to examine the overall clinical performance of low shrinkage giomer resin with equivalent success rates when compared to other restorative materials. The aim of the current study is to evaluate the effect of giomer in maintaining pulp health and dentin bridge formation after partial caries removal in permanent teeth with deep occlusal carious lesion when compared to resin composite restoration.
Sham training will be performed 5 times a week for 4 weeks using a mock asthma inhaler filled with 5.5 mg lactose powder. Subjects will be instructed to inhale the powder according to inhaler instructions and to then perform one full inspiration to total lung capacity using custom-made, low resistance tubing, which elicits minimal resistance to breathing.
OBJECTIVE: Despite the high prevalence of obesity and the clustering of risk by neighborhood, few studies have examined characteristics which promote healthy child weight in neighborhoods with high obesity risk. We aimed to identify protective factors for children living in neighborhoods with high obesity risk.
METHODS: We identified neighborhoods with high obesity risk using geolocated electronic health record data with measured body mass index (BMI) from well-child visits (2012-2017). We then recruited caregivers with children aged 5 to 13 years who lived in census tracts with mean child BMI percentile ≥72 (February 2020-August 2021). We used sequential mixed methods (quantitative surveys, qualitative interviews) to compare individual, interpersonal, and perceived neighborhood factors among families with children at a healthy weight (positive outliers [PO]) versus families with ≥1 child with overweight or obesity (controls). Regression models and comparative qualitative analysis were used to identify protective characteristics.
RESULTS: Seventy-three caregivers participated in the quantitative phase (41% PO; 34% preferred Spanish) and twenty in the qualitative phase (50% PO; 50% preferred Spanish). The frequency of healthy caregiver behaviors was associated with being a PO (Family Health Behavior Scale Parent Score adjusted β 3.67; 95% CI 0.52-6.81 and qualitative data). Protective factors also included caregivers' ability to minimize the negative health influences of family members and adhere to family routines.
CONCLUSIONS: There were few differences between PO and control families. Support for caregiver healthy habits and adherence to healthy family routines emerged as opportunities for childhood obesity prevention in neighborhoods with high obesity risk.
FMT capsules XBI-302 will be administered orally every two weeks for 12 weeks and then every four weeks for 12 weeks. Nivolumab will be intravenously infused every two weeks for 24 weeks.
Renal fibrosis lacks effective nephroprotective drugs in clinical settings due to poor accumulation of therapeutic agents in damaged kidneys, underscoring the urgent need for advanced renal-targeted delivery systems. Herein, we exploited the significantly increased expression of the leucine-rich α-2 glycoprotein 1 (LRG1) protein during renal fibrosis to develop a novel drug delivery system. Our engineered nanocarrier, DENNM, preferentially targets fibrotic kidneys via the decorated ET peptide's high affinity for LRG1. Once internalized by damaged renal cells, DENNM releases its encapsulated nintedanib, triggered by the active caspase-3 protease, disrupting the nanomedicine's structural integrity. The released nintedanib effectively reduces the level of expression of the extracellular matrix and impedes the progression of renal fibrosis by inhibiting the transforming growth factor-β (TGF-β)-Smad2/3 pathway. Our comprehensive in vitro and in vivo studies validate DENNM's antifibrotic efficacy, emphasizing LRG1's potential in renal targeted drug delivery and introducing an innovative approach to nanomedicine for treating renal fibrosis.
In Part 1, participants will receive the following treatments: Treatment A: Two low doses of seltorexant tablets (reference formulation), Treatment B: High dose of seltorexant tablet (Test formulation 1), Treatment C: High dose of seltorexant tablet (Test formulation 2), Treatment D: Two low doses of seltorexant tablets (Test formulation 3), Treatment E: Two low doses of seltorexant tablets (Test formulation 4), Treatment F: Two low doses of seltorexant tablets (Test formulation 5), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-6). There will be a washout Period of 7 to 14 days from dosing on Day 1 of each treatment period.
Recent studies have identified exposure to environmental levels of ozone as a risk factor for the development of acute respiratory distress syndrome (ARDS), a severe form of acute lung injury (ALI) that can develop in humans with sepsis. The aim of this study was to develop a murine model of ALI to mechanistically explore the impact of ozone exposure on ARDS development. Mice were exposed to ozone (0.8 ppm, 3 h) or air control followed 24 h later by intravenous administration of 3 mg/kg lipopolysaccharide (LPS) or PBS. Exposure of mice to ozone + LPS caused alveolar hyperplasia; increased BAL levels of albumin, IgM, phospholipids, and proinflammatory mediators including surfactant protein D and soluble receptor for advanced glycation end products were also detected in BAL, along with markers of oxidative and nitrosative stress. Administration of ozone + LPS resulted in an increase in neutrophils and anti-inflammatory macrophages in the lung, with no effects on proinflammatory macrophages. Conversely, the numbers of resident alveolar macrophages decreased after ozone + LPS; however, expression of Nos2, Arg1, Cxcl1, Cxcl2, Ccl2 by these cells increased, indicating that they are activated. These findings demonstrate that ozone sensitizes the lung to respond to endotoxin, resulting in ALI, oxidative stress, and exacerbated pulmonary inflammation, and provide support for the epidemiologic association between ozone exposure and ARDS incidence.
PURPOSE: The Global Leader Initiative on Malnutrition (GLIM) criteria were developed in 2018 as a global indicator of malnutrition, and the term 'malnutrition-sarcopenia syndrome' was established. Recently, it has been reported that fluctuations in blood glucose are related to sarcopenia. In this study, we investigated the effects of glucose fluctuations on malnutrition after gastrectomy using a continuous glucose monitoring (CGM) device.
METHODS: We analyzed the data of 69 patients with gastric cancer (GC) who underwent curative gastrectomy between November 2017 and December 2020. CGM was performed over a 2-week period at 1 month and 1 year after surgery. The GLIM criteria included weight loss, the body mass index (BMI), and the psoas muscle mass index (PMI).
RESULTS: One year after surgery, 25 and 35 patients had severe and moderate malnutrition, respectively. The time below range (TBR) (percent of time the glucose concentration was < 70 mg/dL) and nocturnal (00:00-06:00) TBR were significantly higher in the severe malnutrition group than in the other groups (TBR: normal/moderate 17.9% vs. severe 21.6%, P = 0.039, nocturnal TBR; normal/moderate 30.6% vs. severe 41.1%, P = 0.034).
CONCLUSIONS: Post-gastrectomy hypoglycemia, including long nocturnal hypoglycemia, was higher in severely malnourished patients than in other patients even 1 year after surgery. Prevention of nocturnal hypoglycemia may be the key to improving malnutrition following gastrectomy.
The embodiments herein relate to a therapeutically active composition for the treatment, inhibition or attenuation of a virus. The composition comprises an effective amount of a sulfur containing compound along with one or more pharmaceutically acceptable carriers or excipients. The sulfur containing compound impairs a disulfide bond of a plurality of virus. The plurality of virus includes  Ebola  virus, herpes virus, dengue virus, smallpox virus, measles virus, mumps rubella virus, HIV (human immunodeficiency virus), Lassa fever virus and yellow fever virus, and even cancer, solid tumors, especially the fibrosarcoma tumor. The sulfur containing compound is sodium thiosulfate (Na 2 S 2 O 3 ) (“STS”). The composition is given orally, intravenously, inhalation, intravesical, vaginal, rectal, sublingual, ophthalmic, or topical.
Use of preformed solid matrices in the field of bone regeneration to achieve volume increases both horizontally and vertically. One of the drawbacks of current formulations is that the matrices are split due to the lack of rigidity when they are fixed by osteosynthesis screws to the maxillary bones. In this case, due to the lack of rigidity, we must add the poor resorption capacity of hydroxyapatite, which makes rapid remodeling of the bone difficult. In an attempt to solve the problems previously presented, the use of more rigid and perforated synthetic blocks for their screwing in bone regeneration procedures has been studied. The idea of designing already perforated blocks for the entry of an osteosynthesis screw at the moment of realization reduces the possibility of fracture of the material that usually occurs when drilling with cutters, facilitating the technique. We consider this solution as a real alternative to the use of antologous bone blocks. (Machine-translation by Google Translate, not legally binding)
Tiotropium bromide inhalation powder consists of tiotropium bromide inhalation powder capsules and a LupinHaler device. Each white opaque, hypromellose tiotropium bromide inhalation powder capsule contains a dry powder consisting of 18 mcg tiotropium (equivalent to 22.5 mcg tiotropium bromide monohydrate USP) blended with lactose monohydrate (which may contain milk proteins).

The contents of tiotropium bromide inhalation powder capsules are intended for oral inhalation only, and are intended for administration only with the LupinHaler device.

The active component of tiotropium bromide inhalation powder is tiotropium. The drug substance, tiotropium bromide monohydrate, is an anticholinergic with specificity for muscarinic receptors. It is chemically described as (1α, 2β, 4β, 5α, 7β)-7-[(Hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo [3.3.1.02,4] nonane bromide monohydrate. It is a synthetic, non-chiral, quaternary ammonium compound. Tiotropium bromide is a white or yellowish white powder. It is sparingly soluble in water and soluble in methanol.

The structural formula is:

Tiotropium bromide (monohydrate) has a molecular mass of 490.4 and a molecular formula of C19H22NO4S2Br • H2O.

The LupinHaler device is an inhalation device used to inhale the dry powder contained in the tiotropium bromide inhalation powder capsule. The dry powder is delivered from the LupinHaler device at flow rates as low as 20 L/min. Under standardized in vitro testing, the LupinHaler device delivers a mean of 10.4 mcg tiotropium when tested at a flow rate of 39 L/min for 3.1 seconds (2 L total). In a study of 26 adult patients with COPD and severely compromised lung function [mean FEV1 1.02 L (range 0.45 to 2.24 L); 37.6% of predicted (range 16% to 65%)], the median peak inspiratory flow (PIF) through the LupinHaler device was 30.0 L/min (range 20.4 to 45.6 L/min). The amount of drug delivered to the lungs will vary depending on patient factors such as inspiratory flow and peak inspiratory flow through the LupinHaler device, which may vary from patient to patient, and may vary with the exposure time of the tiotropium bromide inhalation powder capsule outside the blister pack.
Patients receive PI3K inhibitor BYL719 PO daily on days 1-21 and ado-trastuzumab emtansine IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Aim: Treatment effects among anticoagulant-treated patients with venous thromboembolism (VTE) and cancer across tumor types were evaluated. Methods: Patients initiating an anticoagulant within 30 days after VTE were identified. After inverse probability treatment weighting, patients were stratified by tumor type. Interactions between treatment and tumor type on recurrent VTE, major bleeding and clinically relevant non-major bleeding were assessed using Cox proportional hazard models. Results: Treatment effects were generally not significantly different among patients with or without the following cancer types: prostate, breast, lung, pancreatic or multiple myeloma. Few significant interactions were observed for lung and pancreatic cancer. Conclusion: Anticoagulant treatment effects were generally consistent across tumor types. The significant interactions may indicate tumor-specific effects of anticoagulants, but further research is needed.
Group 2 (treatment group) will be given the Jamboxx musical device plus the Jamboxx respiratory therapy device. The respiratory therapy device is similar to the music device, but with specially designed games that guide the user through breathing exercises intended to strengthen the lungs.
FIELD: organic chemistry. SUBSTANCE: invention relates to thiosubstituted, nitrogen-containing, heterocyclic phosphonate compounds including phosphonates, phosphonoalkylphosphonates, phosphonocarboxylates and phosphonosulfonates, and their pharmaceutically acceptable salts and ethers also. Invention relates to pharmaceutical compositions containing safety and effective amount of this compound and pharmaceutically acceptable vehicles. Also, invention relates to method of treatment or prophylaxis of pathological states that involve anomal calcium and phosphate metabolism in human and other mammalian including for treatment and prophylaxis of osteoporosis and arthritis, especially, rheumatic arthritis and osteoarthritis. Method involves administration of effective dose of compound or composition to human or other mammalian. These compounds show the general structure (I) where at least one of substituents R, R, Ror Rmust be SRor RSR.. EFFECT: improved method of synthesis, enhanced effectiveness of treatment and prophylaxis.
PURPOSE:To improve the antitumor activity, by treating an aqueous solution of the product, which has been obtained by purifying the extract of neem bark extracted with hot water, with molecular sieves and subjecting it to a specific treatment. CONSTITUTION:The extract of neem bark extracted with hot water is purified by the alcohol precipitation method or diaphragm membrane method to obtain an aqueous solution of the purified matter. The aqueous solution is treated with molecular sieves having a fractionation molecular weight of from 1X10<3>-1X10<5> to 1X10<3>-2X10<5> to obtain three polysaccharide fractions. The polysaccharide obtained from the first fraction of the three fractions is dissolved in water and hydrolyzed with alpha-amylase and the digested materials are removed to obtain a non-digested polysaccharide. The non-digested polysaccharide is subjected to a treatment with molecular sieves having a fractionation molecular weight of 1X10<3>-2X10<5>. A quaternary amine saccharide precipitating agent is added to the liquid which has been passed through them to remove said saccharides, thereby obtaining neutral saccharides. Then, an aqueous solution of boric acid is added to the resulting neutral saccharides so that the pH may be brought to 8-9, thereby producing a precipitate. The boric acid is removed from the precipitate, and the precipitate is dissolved in water. The solution is treated with molecular sieves having a fractionation molecular weight of 2X10<3>-3X10<5> to obtain three polysaccharide fractions. From the three fractions, polysaccharides CSP-I, CSP-II and CSP-III are obtained, respectively.
In line with the number of patients obtained after sample size calculation, the study was completed on 40 patients who met the inclusion criteria. Patients were healthy, volunteer individuals who required excision of the epulis fissuratum or frenulum with the indication of preprosthetic surgery. 2 groups were formed by simple randomization with 20 patients in the tablet group and 20 patients in the spray group. After the surgical procedure, tablet and spray flurbiprofen were prescribed according to the groups. Apart from these, paracetamol, chlorhexidine gluconate + benzidamine hydrochloride mouthwash were prescribed to all patients as rescue analgesics. The tissue fragments removed from the patients who underwent epulis excision were sent for histopathologic evaluation and confirmed.
Recurrence after colorectal cancer resection is rarely documented in the general population while a key clinical determinant for patient survival. We identified 8785 patients with colorectal cancer diagnosed between 2010 and 2013 and clinically followed up to 2020 in 15 cancer registries from seven European countries (Bulgaria, Switzerland, Germany, Estonia, France, Italy, and Spain). We estimated world age-standardized net survival using a flexible cumulative excess hazard model. Recurrence rates were calculated for patients with initially resected stage I, II, or III cancer in six countries, using the actuarial survival method. The proportion of nonmetastatic resected colorectal cancers varied from 58.6% to 78.5% according to countries. The overall 5-year net survival by country ranged between 60.8% and 74.5%. The absolute difference between the 5-year survival extremes was 12.8 points for stage II (Bulgaria vs Switzerland), 19.7 points for stage III (Bulgaria vs. Switzerland) and 14.8 points for Stage IV and unresected cases (Bulgaria vs. Switzerland or France). Five-year cumulative rate of recurrence among resected patients with stage I-III was 17.7%. As compared to the mean of the whole cohort, the risk of developing a recurrence did not differ between countries except a lower risk in Italy for both stage I/II and stage III cancers and a higher risk in Spain for stage III. Survival after colorectal cancer differed across the concerned European countries while there were slight differences in recurrence rates. Population-based collection of cancer recurrence information is crucial to enhance efforts for evidence-based management of colorectal cancer follow up.
To methods, systems, apparatus, and/or computer programs. Mass spectrometer test data (e.g., a blood sample of a medical patient) can be associated with metadata information. The associated metadata information may be associated with a medical patient. The subset of sample reference libraries may be based on associated metadata information. According to an embodiment, the sample reference library may include multiple sets of mass spectrometer reference data. Embodiments match mass spectrometer test data with mass spectrometer reference data of a selected subset of a sample reference library. Embodiments determine characteristic information of a source of mass spectrometer test data (e.g., a medical patient) based on known characteristics of matching mass spectrometer reference data.
The invention relates to a use of a Solanum integrifolium Poir. extract as an anti-inflammatory agent by applying an effective does of a green fruit extract of Solanum integrifolium Poir. to inflammatory cells for inhibiting expression of inflammation-related genes and production of nitric oxide (NO), and for stimulating expression of heme oxygenase 1 (HO-1) and activation of extracellular signal-regulated kinase (ERK). The Solanum integrifolium Poir. extract is manufactured by at least one extraction step comprising extracting with an organic solvent first and partitioning with various solvents gradually. Accordingly, the Solanum integrifolium Poir. Extract can be utilized in manufacturing cosmetic compositions, health food, and pharmaceutical composition for anti-inflammation, so as to slow down or reduce inflammation.
PURPOSE:To obtain the titled cosmetic having excellent moisturizing effect, effective in improving chapped skin and cuticle layer and exhibiting remarkable skin-beautifying effect, by using a specific flavonoid glycoside as an active component and adding the component to a skin cosmetic base. CONSTITUTION:At least one kind of the compound of formula (R1, R2, R3, R4 and R5 are H, OH, OCH3, glucose residue or O-glucose-rhamnose residue) is compounded to a conventional skin cosmetic base used usually in a cosmetic such as lotion, cream, milky lotion, etc. The amount of the flavonoid glycoside is 0.1-10.0wt%, preferably 0.5-5.0wt% based on the whole skin cosmetic. The flavonoid glycoside of formula is e.g. 6,8-di-C-glucosylapigenin, etc., which can be extracted e.g. form lemon peel.
Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.
When JITAIs are turned ON, the base self-help app will be used to deliver targeted, personalized and automated interventions during algorithm-identified moments when participants could benefit from receiving an intervention for improving two key areas including 1) treatment adherence, and 2) skills utilization based on responses (or lack thereof) in self-help app. When JITAIs are turned OFF, participants will not receive interventions in real-time on the base self-help app.